126 related articles for article (PubMed ID: 37203200)
1. A technology evaluation of the Onyx Frontier drug-eluting stent.
Leone PP; Assafin M; Scotti A; Gonzalez M; Mignatti A; Dawson K; Rauch J; Khaliq A; Bliagos D; Latib A
Expert Opin Drug Deliv; 2023 May; 20(5):689-701. PubMed ID: 37203200
[TBL] [Abstract][Full Text] [Related]
2. Device profile of the Resolute Onyx Zotarolimus eluting coronary stent system for the treatment of coronary artery disease: overview of its safety and efficacy.
Blum M; Cao D; Mehran R
Expert Rev Med Devices; 2020 Apr; 17(4):257-265. PubMed ID: 32154750
[No Abstract] [Full Text] [Related]
3. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
[TBL] [Abstract][Full Text] [Related]
4. Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years.
Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Jessurun GAJ; Schotborgh CE; Roguin A; Danse PW; Benit E; Aminian A; van Houwelingen KG; Schramm AR; Stoel MG; Somi S; Hartmann M; Linssen GCM; von Birgelen C
JACC Cardiovasc Interv; 2020 May; 13(9):1100-1109. PubMed ID: 32381186
[TBL] [Abstract][Full Text] [Related]
5. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
6. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients.
Kandzari DE; Kirtane AJ; Windecker S; Latib A; Kedhi E; Mehran R; Price MJ; Abizaid A; Simon DI; Worthley SG; Zaman A; Choi JW; Caputo R; Kanitkar M; McLaurin B; Potluri S; Smith T; Spriggs D; Tolleson T; Nazif T; Parke M; Lee LC; Lung TH; Stone GW;
Circ Cardiovasc Interv; 2020 Nov; 13(11):e009565. PubMed ID: 33167705
[TBL] [Abstract][Full Text] [Related]
7. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
[TBL] [Abstract][Full Text] [Related]
8. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
Rozemeijer R; Stein M; Voskuil M; van den Bor R; Frambach P; Pereira B; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Agostoni P; Roes KC; Doevendans PA; Stella PR;
Circulation; 2019 Jan; 139(1):67-77. PubMed ID: 30586704
[TBL] [Abstract][Full Text] [Related]
9. First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter.
Price MJ; Saito S; Shlofmitz RA; Spriggs DJ; Attubato M; McLaurin B; Popma Almonacid A; Brar S; Liu M; Moe E; Mehran R
JACC Cardiovasc Interv; 2017 Jul; 10(14):1381-1388. PubMed ID: 28728650
[TBL] [Abstract][Full Text] [Related]
10. Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials.
Konigstein M; Smits PC; Love MP; Ben-Yehuda O; Ozan MO; Liu M; Perlman GY; Leon MB; Stone GW; Kandzari DE
JACC Cardiovasc Interv; 2020 Jan; 13(1):86-93. PubMed ID: 31918946
[TBL] [Abstract][Full Text] [Related]
11. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
Silber S; Serruys PW; Leon MB; Meredith IT; Windecker S; Neumann FJ; Belardi J; Widimsky P; Massaro J; Novack V; Yeung AC; Saito S; Mauri L
JACC Cardiovasc Interv; 2013 Apr; 6(4):357-68. PubMed ID: 23523454
[TBL] [Abstract][Full Text] [Related]
13. One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis.
Wang H; Xie X; Zu Q; Lu M; Chen R; Yang Z; Gao Y
Cardiovasc Diabetol; 2022 Oct; 21(1):220. PubMed ID: 36307791
[TBL] [Abstract][Full Text] [Related]
14. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
[TBL] [Abstract][Full Text] [Related]
15. One-year clinical outcomes of patients treated with polymer-free amphilimus-eluting stents or zotarolimus-eluting stents: A propensity-score adjusted analysis.
Rozemeijer R; van Muiden IG; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Doevendans PA; Voskuil M; Stella PR
Catheter Cardiovasc Interv; 2019 Jul; 94(1):61-69. PubMed ID: 30604493
[TBL] [Abstract][Full Text] [Related]
16. Polymer-Free Biolimus-Eluting Stents or Polymer-Based Zotarolimus-Eluting Stents for Coronary Bifurcation Lesions.
Gallone G; D'Ascenzo F; Ielasi A; Landra F; Stefanini GG; Di Biasi M; Mancone M; Tomai F; Infantino V; Rognoni A; Briguori C; Boccuzzi G; Smolka G; Chiarito M; Capodanno D; Chieffo A; Fabbiocchi F; Poli A; Tespili M; D'Urbano M; Giordano A; Escaned J; De Ferrari GM; Sardella G
Cardiovasc Revasc Med; 2022 Feb; 35():66-73. PubMed ID: 33903036
[TBL] [Abstract][Full Text] [Related]
17. Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State.
Hannan EL; Zhong Y; Wu C; Walford G; Holmes DR; Jacobs AK; Stamato NJ; Venditti FJ; Sharma S; Fergus I; King SB
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1097-105. PubMed ID: 22707353
[TBL] [Abstract][Full Text] [Related]
18. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.
Vardi M; Burke DA; Bangalore S; Pencina MJ; Mauri L; Kandzari DE; Leon MB; Cutlip DE
Catheter Cardiovasc Interv; 2013 Dec; 82(7):1031-8. PubMed ID: 23737390
[TBL] [Abstract][Full Text] [Related]
20. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
